THE PRISMA-ECONEVAL 2026 STATEMENT: EXTENSION OF PRISMA AS A REPORTING GUIDELINE FOR SYSTEMATIC REVIEWS OF HEALTH ECONOMIC EVALUATIONS
Author(s)
Joseph Kwon, PhD1, Phuong Bich Tran, PhD1, Ewan Tomeny, PhD2, Teodoro D'Agostino, MSc1, Anastasios Bastounis, PhD3, Andrew Booth, PhD3, Matthew Page, PhD4, Kednapa Thavorn, PhD5, Sally Hopewell, PhD6, Rafael Pinedo-Villanueva, PhD7, Richard Grant, BA8, Sophie Staniszewska, DPhil9, Stavros Petrou, PhD1.
1Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, United Kingdom, 2Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 3Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 4Methods in Evidence Synthesis Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, 5School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, United Kingdom, 7Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 8Patient and Public Involvement (PPI) Representative, Warwick, Oxford, Liverpool, Coventry, United Kingdom, 9Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
1Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, United Kingdom, 2Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 3Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 4Methods in Evidence Synthesis Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, 5School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, United Kingdom, 7Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 8Patient and Public Involvement (PPI) Representative, Warwick, Oxford, Liverpool, Coventry, United Kingdom, 9Warwick Applied Health, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
OBJECTIVES: Systematic reviews of health economic evaluations (SR-HEEs) are increasingly used to inform policies and decisions about the allocation of healthcare resources, including reimbursement and coverage decisions by health technology assessment (HTA) agencies, and to identify methodological gaps in health economic evaluation. Transparent, complete, and accurate reporting of SR-HEEs is therefore essential to support critical appraisal and appropriate use of review findings. We here present the extension to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement for SR-HEEs: the PRISMA-EconEval 2026 statement.
METHODS: The development of PRISMA-EconEval 2026 followed four stages according to recommendations on reporting guideline development and modelled on approaches used in previous extensions of PRISMA: (1) scoping review of methodological literature on conduct and reporting of SR-HEE; (2) multi-round Delphi survey of interest holders; (3) consensus meeting; and (4) post-consensus piloting. A Public Involvement Reference Group comprising patient and public representatives participated in all stages.
RESULTS: PRISMA-EconEval 2026 statement includes 34 reporting items and is designed for all SR-HEEs, irrespective of their objective(s). Twelve items remained unchanged from PRISMA 2020, 15 were modified, and seven were new additions including conceptual framework, patient and public involvement and engagement, and artificial intelligence and language model use. The statement is primarily designed for systematic reviews of full health economic evaluations, rather than non-systematic reviews and systematic reviews of partial economic evaluations. The statement is intended to guide reporting of SR-HEEs. Readers are encouraged to consult the accompanying Explanation and Elaboration paper, which describes the essential and additional elements of each reporting item and provides exemplars.
CONCLUSIONS: PRISMA-EconEval 2026 statement provides guidance for researchers reporting SR-HEEs, as well as reviewers and editors involved in evaluating SR-HEEs. It may also support systematic reviewers during review planning and conduct and facilitate healthcare decision-making by HTA agencies and other decision-makers.
METHODS: The development of PRISMA-EconEval 2026 followed four stages according to recommendations on reporting guideline development and modelled on approaches used in previous extensions of PRISMA: (1) scoping review of methodological literature on conduct and reporting of SR-HEE; (2) multi-round Delphi survey of interest holders; (3) consensus meeting; and (4) post-consensus piloting. A Public Involvement Reference Group comprising patient and public representatives participated in all stages.
RESULTS: PRISMA-EconEval 2026 statement includes 34 reporting items and is designed for all SR-HEEs, irrespective of their objective(s). Twelve items remained unchanged from PRISMA 2020, 15 were modified, and seven were new additions including conceptual framework, patient and public involvement and engagement, and artificial intelligence and language model use. The statement is primarily designed for systematic reviews of full health economic evaluations, rather than non-systematic reviews and systematic reviews of partial economic evaluations. The statement is intended to guide reporting of SR-HEEs. Readers are encouraged to consult the accompanying Explanation and Elaboration paper, which describes the essential and additional elements of each reporting item and provides exemplars.
CONCLUSIONS: PRISMA-EconEval 2026 statement provides guidance for researchers reporting SR-HEEs, as well as reviewers and editors involved in evaluating SR-HEEs. It may also support systematic reviewers during review planning and conduct and facilitate healthcare decision-making by HTA agencies and other decision-makers.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
P52
Topic
Economic Evaluation, Health Technology Assessment, Study Approaches
Topic Subcategory
Literature Review & Synthesis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas